Titan Spine experienced several milestones in the first quarter of 2017 as a company and with the Endoskeleton titanium interbody fusion device that includes nanoLOCK surface technology.
Here are five things to know:
1. The company reported record sales in the first quarter of 2017.
2. There have now been 1,000 implantations of the nanoLOCK Endoskeleton device since its launch.
3. Seventy-four surgeons in 52 hospitals across 26 states are using the nanoLOCK technology.
4. Since December 2016, nanoLOCK sales volume increased 270 percent.
5. The company tripled the number of area vice presidents and regional managers in less than one year.
Last year CMS created a new technology ICD-10 code for the nanotextured interbody fusion device that drove an increase in the number of hospitals and surgeons using the device. "Our Q1 achievements reflect the growing demand from our current surgeon base plus new relationships we have made with surgeon adopters that are beginning to embrace the benefits of nanotechnology for their patients," said Executive Vice President of Sales Steve Cichy.